Laboratory Corp. of America Holdings (LH)

168.26
NYSE : Health Services
Prev Close 168.26
Day Low/High 0.00 / 0.00
52 Wk Low/High 134.19 / 181.72
Avg Volume 668.60K
Exchange NYSE
Shares Outstanding 102.00M
Market Cap 16.98B
EPS 12.40
P/E Ratio 13.73
Div & Yield N.A. (N.A)

Latest News

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 To Accrue Contingent Interest

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 To Accrue Contingent Interest

LabCorp® (NYSE: LH) announced today that for the period of March 12, 2018 to September 11, 2018, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will accrue (subject to the terms of the Zero...

Covance Forms Immunology & Immunotoxicology Unit Focused On Biologic Drug Development

Covance Forms Immunology & Immunotoxicology Unit Focused On Biologic Drug Development

LabCorp® (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business has formed a global immunology and immunotoxicology (I&I) unit dedicated to the...

LabCorp Is Scheduled To Present At The 2018 Barclays Global Healthcare Conference

LabCorp Is Scheduled To Present At The 2018 Barclays Global Healthcare Conference

LabCorp® (NYSE: LH) today announced it will participate at the 2018 Barclays Global Healthcare Conference.

LabCorp Partners With Cheeriodicals Through Community Service Campaign To Florida Hospital Memorial Medical Center And Halifax Health Medical Center

LabCorp Partners With Cheeriodicals Through Community Service Campaign To Florida Hospital Memorial Medical Center And Halifax Health Medical Center

As part of a community service campaign, an enthusiastic group of LabCorp employees teamed up with Cheeriodicals to assemble and deliver 128 big green boxes to children patients at Florida Hospital Memorial Medical Center...

Covance Enters Into Strategic Technology Agreement With GSK

Covance Enters Into Strategic Technology Agreement With GSK

LabCorp® (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business has entered into a strategic technology agreement with GlaxoSmithKline plc (GSK).

LabCorp Is Scheduled To Present At The 39th Annual Raymond James Institutional Investors Conference

LabCorp Is Scheduled To Present At The 39th Annual Raymond James Institutional Investors Conference

LabCorp® (NYSE: LH) today announced it will participate at the 39th Annual Raymond James Institutional Investors Conference.

LabCorp To Host Investor And Analyst Day On February 27, 2018

LabCorp To Host Investor And Analyst Day On February 27, 2018

LabCorp® (NYSE: LH), a leading global life sciences company, will host an Investor and Analyst Day for institutional investors and financial analysts in New York City on Tuesday, February 27, 2018.

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

Centene and Laboratory Corp. of America were among the healthcare stocks in the green on Tuesday, Feb. 6, amid a volatile trading day in the stock market.

LabCorp Announces Record 2017 Fourth Quarter And Full Year Results And Provides 2018 Guidance

LabCorp Announces Record 2017 Fourth Quarter And Full Year Results And Provides 2018 Guidance

LabCorp ® (or the Company) (NYSE: LH) today announced results for the fourth quarter and year ended December 31, 2017, and provided 2018 guidance.

LabCorp Named To FORTUNE Magazine's 2018 List Of 'World's Most Admired Companies'

LabCorp Named To FORTUNE Magazine's 2018 List Of 'World's Most Admired Companies'

Laboratory Corporation of America ® Holdings (LabCorp) (NYSE: LH), a leading global life sciences company, today announced that it has been named to FORTUNE magazine's 2018 List of World's Most Admired Companies.

Covance Introduces Dedicated Offering Designed For Biotech, Medical Device And Diagnostics Companies

Covance Introduces Dedicated Offering Designed For Biotech, Medical Device And Diagnostics Companies

LabCorp® (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business has introduced a dedicated offering for biotech, medical device and diagnostics...

LabCorp Is Scheduled To Present At The 36th Annual J.P. Morgan Healthcare Conference

LabCorp Is Scheduled To Present At The 36th Annual J.P. Morgan Healthcare Conference

LabCorp® (NYSE: LH) today announced it will participate at the 36th Annual J.

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

LabCorp ® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Supports American Clinical Laboratory Association Lawsuit On PAMA Final Rule

LabCorp Supports American Clinical Laboratory Association Lawsuit On PAMA Final Rule

LabCorp (NYSE: LH), a leading global life sciences company, today issued the following statement regarding the lawsuit filed by the American Clinical Laboratory Association (ACLA) against the Acting Secretary of the U.

LabCorp Announces New Expanded Use For PD-L1 Test With Bristol-Myers Squibb's OPDIVO®

LabCorp Announces New Expanded Use For PD-L1 Test With Bristol-Myers Squibb's OPDIVO®

LabCorp (NYSE: LH) a leading global life sciences company, today announced the U.

LabCorp Receives 2017 Partnership Award From Be The Match®

LabCorp Receives 2017 Partnership Award From Be The Match®

LabCorp, (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, proudly announces that it received the 2017 Partnership Award from Be The Match® on November 11 at...

LabCorp Earns 100 Percent On Human Rights Campaign Foundation's 16th Annual Scorecard On LGBTQ Workplace Equality

LabCorp Earns 100 Percent On Human Rights Campaign Foundation's 16th Annual Scorecard On LGBTQ Workplace Equality

LabCorp (NYSE: LH), a leading global life sciences company, announced that it received a perfect score of 100 percent on the 2018 Corporate Equality Index (CEI), a national benchmarking survey and report on corporate...

LabCorp Is Scheduled To Present At The 26th Annual Credit Suisse Healthcare Conference

LabCorp Is Scheduled To Present At The 26th Annual Credit Suisse Healthcare Conference

LabCorp ® (NYSE: LH) today announced it will participate at the 26th Annual Credit Suisse Healthcare Conference.

LabCorp And Capital Health Enter Comprehensive Laboratory Partnership

LabCorp And Capital Health Enter Comprehensive Laboratory Partnership

LabCorp® (NYSE: LH), a leading global life sciences company, and Capital Health, the Central New Jersey/Lower Bucks County, Pennsylvania region's leader in providing progressive, quality patient care, announced today...

LabCorp Announces Record Third Quarter Results And Increases 2017 Guidance

LabCorp Announces Record Third Quarter Results And Increases 2017 Guidance

LabCorp ® (or the "Company") (NYSE: LH) today announced results for the third quarter ended September 30, 2017, and increased its 2017 guidance.

Covance Employees Accept Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award (Photo: Business Wire)

Covance Employees Accept Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award (Photo: Business Wire)

LabCorp (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development business (Covance) has been awarded the 2017 Frost & Sullivan Asia Pacific CRO Customer Value Leadership...

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Objects To Proposed PAMA 2018 Medicare Payment Rates For Clinical Laboratory Tests; Calls For Delay In Implementation To Avoid Significant Harm To Medicare Beneficiaries

LabCorp Objects To Proposed PAMA 2018 Medicare Payment Rates For Clinical Laboratory Tests; Calls For Delay In Implementation To Avoid Significant Harm To Medicare Beneficiaries

LabCorp (NYSE: LH), a leading global life sciences company, today issued the following response to the Sept.

LabCorp Presents Nine Studies, Including Novel Research On Improving Genetic Counseling Quality, At The National Society Of Genetic Counselors Annual Conference

LabCorp Presents Nine Studies, Including Novel Research On Improving Genetic Counseling Quality, At The National Society Of Genetic Counselors Annual Conference

LabCorp (NYSE: LH), a leading global life sciences company, announced today that Integrated Genetics, a member of the LabCorp Specialty Testing Group, is presenting the results of nine studies relating to prenatal testing,...

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 To Accrue Contingent Interest

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 To Accrue Contingent Interest

LabCorp® (NYSE: LH) announced today that for the period of September 11, 2017 to March 9, 2018, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon...

LabCorp Named Among "The World's Most Innovative Companies" In Forbes' 2017 Ranking

LabCorp Named Among "The World's Most Innovative Companies" In Forbes' 2017 Ranking

LabCorp® (NYSE: LH), a leading global life sciences company, has been named to Forbes' 2017 ranking of "The World's Most Innovative Companies.

LabCorp Is Scheduled To Present At The Morgan Stanley Global Healthcare Conference

LabCorp Is Scheduled To Present At The Morgan Stanley Global Healthcare Conference

LabCorp® (NYSE:LH) today announced it will participate at the Morgan Stanley Global Healthcare Conference.

LabCorp Completes Acquisition Of Chiltern

LabCorp Completes Acquisition Of Chiltern

LabCorp® (NYSE: LH), a leading global life sciences company, has completed its previously announced acquisition of Chiltern, which will become part of the company's Covance Drug Development business.

TheStreet Quant Rating: A (Buy)